Monday, April 27, 2015
FAIRFIELD-SUISUN, CALIFORNIA
99 CENTS

Merck to pay $3.85B for hepatitis C drug developer

Merck

FILE - This Thursday, Feb. 28, 2013 file photo shows a patch with the Merck logo on a scientist's lab coat in West Point, Pa. Merck on Monday, June 9, 2014 announced it will spend nearly $4 billion for Idenix Pharmaceuticals with a per-share bid that more than triples the hepatitis C drug developer’s latest closing price. (AP Photo/Matt Rourke, File)

By
June 10, 2014 |

TRENTON, N.J. — Merck & Co. will spend about $3.85 billion for Idenix Pharmaceuticals Inc., a small company developing hepatitis C medicines that, together with Merck’s experimental drugs, could produce lucrative combo therapies that quickly cure most patients with the blood-borne virus afflicting tens of millions.

The price for the deal announced Monday — a per-share bid more than triple Friday’s closing price for Cambridge, Massachusetts-based Idenix — seems high. However, the latest hepatitis C medicines command very high prices, the number of patients keeps rising and Merck was bidding against rivals.

Hepatitis C has become one of the hottest categories in drug research as companies race to develop a combination therapy without injections and debilitating side effects. Some have had their promising candidates fail after extensive testing, due to dangerous side effects, but Gilead Sciences Inc. is already raking in billions of dollars from its groundbreaking new drug, Sovaldi.

Merck, based in Whitehouse Station, New Jersey, said it will spend $24.50 in cash for each Idenix share. Idenix closed at $7.23 on Friday, then more than tripled at Monday’s opening bell.

The boards of both companies have approved the deal, which should close in the third quarter.

“Idenix has established a promising portfolio of hepatitis C candidates based on its expertise in (certain) technologies,” Merck’s research head, Dr. Roger Perlmutter, said in a statement.

Three Idenix experimental drugs have reached human testing and one, samatasvir, is in mid-stage testing. It’s in a new drug class called NS5A inhibitors, which disrupt various stages of the virus life cycle. Two other drugs, known as IDX21437 and IDX21459, are in a class called nucleotide prodrugs, which stop the virus from producing genetic material needed to copy itself.

Merck has been testing two drugs together, MK-5172 and MK-8742, that the Food and Drug Administration has deemed a breakthrough therapy. Merck will soon start late-stage testing of the two drugs together and presumably will study them in combinations with the Idenix drugs.

About 4.4 million Americans and an estimated 170 million people worldwide have chronic hepatitis C, the leading cause of liver cancer and, in wealthy countries, the top reason for liver transplants. In the U.S., it kills more than 16,000 people a year.

While most people infected don’t know it because there are no obvious symptoms, a growing number have been identified and started treatment in the last few years as more effective medicines have been approved. That number is expected to grow as the U.S. population ages and patients infected decades ago through intravenous drug use, or from blood transfusions before the early 1990s, are diagnosed.

Merck has been a major player in hepatitis C since acquiring Schering-Plough in 2009. Back then, treatment was limited to twice-a-day pills called ribavirin and self-injections of a long-acting, synthetic form of immune system protein interferon. Treatment often lasted 48 weeks, only about 40 percent of patients were cured, and flu-like symptoms and other side effects of the interferon kept many patients from completing treatment.

In 2011, the FDA approved two drugs in a class called protease inhibitors, Merck’s Victrelis and Incivek from Vertex Pharmaceuticals. Those are taken with ribavirin and interferon, work by blocking an enzyme needed for copying the virus, and boost the cure rate to about 75 percent. But they require patients to take a dozen pills a day, and still endure flu-like side effects.

Last December, the FDA approved Gilead’s once-a-day pill Sovaldi, which cures 80 percent to 90 percent of patients, without the interferon injections and side effects.

Physicians quickly embraced it, and Sovaldi racked up more than $2 billion in sales in its first full quarter on sale, considered the best new drug launch in history. That’s mainly because of Sovaldi’s high price, about $1,000 per pill, or $84,000 for a 12-week treatment course, which continues to draw criticism from patients, insurers and government.

Sovaldi appears poised to dominate the hepatitis C market, greatly outselling Johnson & Johnson’s Olysio, approved about the same time. But there’s plenty of room for Merck and others because Sovaldi can’t be taken by some patients with multiple illnesses or certain hepatitis C subtypes.

In afternoon trading, Idenix shares climbed $16.76 to $23.99. Merck shares slipped 5 cents to $57.80.

Shares of another hepatitis C drug developer, Achillion Pharmaceuticals Inc., now seen as a potential takeover target, climbed 58 percent to $4.55.

 

The Associated Press

The Associated Press

LEAVE A COMMENT

Discussion | No comments

The Daily Republic does not necessarily condone the comments here, nor does it review every post. Read our full policy

.

Solano News

Vacaville eyes ban on medical marijuana grows

By Ryan McCarthy | From Page: A1

 
County action speeds Solano fairgrounds plan to next phase

By Kevin W. Green | From Page: A1 | Gallery

Paint the Town Purple; and Roxie

By Tony Wade | From Page: A2

 
Farmers markets herald return of summer

By Susan Hiland | From Page: A3

 
City Coach hosts first block party

By Susan Hiland | From Page: A3

Bid Corderos Park, city staff recommends

By Ryan McCarthy | From Page: A3

 
White minister fought for civil rights in the south

By Amy Maginnis-Honey | From Page: A3 | Gallery

Denim and Diamonds fundraiser set May 16

By Amy Maginnis-Honey | From Page: A4

 
Crash claims life of Concord teen

By Amy Maginnis-Honey | From Page: A4

Biz Buzz: Committee schedules contractors breakfast

By Kevin W. Green | From Page: B7

 
Biz Buzz: Budweiser kicks off new parks campaign

By Susan Hiland | From Page: B7

Biz Buzz: Dutch Bros. plans ALS fundraiser

By Susan Hiland | From Page: B7

 
Biz Buzz: Company schedules pasta class

By Susan Hiland | From Page: B7

 
Biz Buzz: NorthBay offers extended hours for primary care

By Kevin W. Green | From Page: B7 | Gallery

 
Biz Buzz: Retail store helps those with autism

By Susan Hiland | From Page: B7

.

US / World

Picture it: A 1,000-year exposure showing a changing Earth

By The Associated Press | From Page: A1

 
Quake agony revealed quietly on trip from Nepal airport

By The Associated Press | From Page: A5

 
Corinthian Colleges to shut down all 28 remaining campuses

By The Associated Press | From Page: A5

No time to lose: Global response to Nepal quake gears up

By The Associated Press | From Page: A5

 
Japan’s prime minister goes to US to showcase close ties

By The Associated Press | From Page: A5

Israel says airstrike on Syrian border targeted militants

By The Associated Press | From Page: A5

 
Family, friends in Baltimore mourn death of arrested man

By The Associated Press | From Page: A5

‘Batman’ killer studied brain disorders before mass murder

By The Associated Press | From Page: A5

 
Image from the quake: Heavy damage in Nepal ancient city

By The Associated Press | From Page: A5

Fighting rages in Yemen’s 3rd-largest city, strikes continue

By The Associated Press | From Page: A5

 
Mountaineers, guides stream from Everest after avalanche

By The Associated Press | From Page: A5

Putin accuses US of supporting separatists in Russia

By The Associated Press | From Page: A5

 
Death toll in Nepal quake rises to more than 3,200

By The Associated Press | From Page: A5

Late spring complicates already perilous amphibian migration

By The Associated Press | From Page: A5

 
.

Living

Community Calendar: April 27, 2015

By Susan Hiland | From Page: A2

 
Today in history: Monday, April 27, 2015

By The Associated Press | From Page: A2

Horoscope: April 28, 2015

By Holiday Mathis | From Page: B5

 
Parenting: How to set boundaries on screen time

By The Washington Post | From Page: B5

Horoscope: April 27, 2015

By Holiday Mathis | From Page: A7

 
My husband doesn’t want me to redecorate home he had with first wife

By Kathy Mitchell and Marcy Sugar | From Page: A7

.

Entertainment

TVGrid April 27

By Daily Republic Syndicated Content | From Page: B6

 
TVGrid April 28

By Daily Republic Syndicated Content | From Page: B7

.

Sports

Warriors confident after sweep of Pelicans

By The Associated Press | From Page: B1

 
Giants-Rockies game postponed by rain

By The Associated Press | From Page: B1

 
American Pharoah completes final pre-Kentucky Derby workout

By The Associated Press | From Page: B2

Newgarden claims first IndyCar Series win not far from home

By The Associated Press | From Page: B2

 
Justin Rose wins in New Orleans for 7th PGA Tour title

By The Associated Press | From Page: B2

Wall, Beal lead Wiz past Raptors 125-94 in Game 4 for sweep

By The Associated Press | From Page: B2

 
Paul, Clippers even series with 114-105 win over Spurs

By The Associated Press | From Page: B2

 
Ko wins Swinging Skirts for 2nd straight year

By The Associated Press | From Page: B2

Motorcycle rider from Livermore killed in Nevada race

By The Associated Press | From Page: B2

 
Billy Andrade and Joe Durant win Legends of Golf

By The Associated Press | From Page: B2

Cavs sweep Celts as James scores 27 in 101-93 victory

By The Associated Press | From Page: B2

 
It’s here: Fight week begins with Pacquiao caravan to Vegas

By The Associated Press | From Page: B2

.

Business

.

Obituaries

Elizabeth Cepeda

By Nancy Green | From Page: A4, 1 Comment

 
Kirk Noonan

By Nancy Green | From Page: A4, 1 Comment

Sandra King

By Nancy Green | From Page: A4

 
Janis Ruth (Sefzik) Skinner

By Nancy Green | From Page: A4

.

Comics

Baby Blues April 28

By Daily Republic Syndicated Content | From Page: B4

 
Zits April 28

By Daily Republic Syndicated Content | From Page: B4

Pickles April 28

By Daily Republic Syndicated Content | From Page: B4

 
Rose is Rose April 28

By Daily Republic Syndicated Content | From Page: B4

Get Fuzzy April 28

By Daily Republic Syndicated Content | From Page: B4

 
Dilbert April 28

By Daily Republic Syndicated Content | From Page: B4

B.C. April 28

By Daily Republic Syndicated Content | From Page: B4

 
Blondie April 28

By Daily Republic Syndicated Content | From Page: B4

Frank and Ernest April 28

By Daily Republic Syndicated Content | From Page: B4

 
Wizard of Id April 28

By Daily Republic Syndicated Content | From Page: B4

Peanuts April 28

By Daily Republic Syndicated Content | From Page: B4

 
Baldo April 28

By Daily Republic Syndicated Content | From Page: B4

Garfield April 28

By Daily Republic Syndicated Content | From Page: B4

 
Beetle Bailey April 28

By Daily Republic Syndicated Content | From Page: B4

For Better or Worse April 28

By Daily Republic Syndicated Content | From Page: B4

 
Sally Forth April 28

By Daily Republic Syndicated Content | From Page: B4

Bridge April 28

By Daily Republic Syndicated Content | From Page: B5

 
Cryptoquote April 28

By Daily Republic Syndicated Content | From Page: B5

Word Sleuth April 28

By Daily Republic Syndicated Content | From Page: B5

 
Crossword April 28

By Daily Republic Syndicated Content | From Page: B5

Sudoku April 28

By Daily Republic Syndicated Content | From Page: B5

 
Sally Forth April 27

By Daily Republic Syndicated Content | From Page: A6

B.C. April 27

By Daily Republic Syndicated Content | From Page: A6

 
Garfield April 27

By Daily Republic Syndicated Content | From Page: A6

Beetle Bailey April 27

By Daily Republic Syndicated Content | From Page: A6

 
Blondie April 27

By Daily Republic Syndicated Content | From Page: A6

Get Fuzzy April 27

By Daily Republic Syndicated Content | From Page: A6

 
Pickles April 27

By Daily Republic Syndicated Content | From Page: A6

Wizard of Id April 27

By Daily Republic Syndicated Content | From Page: A6

 
Baldo April 27

By Daily Republic Syndicated Content | From Page: A6

Rose is Rose April 27

By Daily Republic Syndicated Content | From Page: A6

 
For Better or Worse April 27

By Daily Republic Syndicated Content | From Page: A6

Zits April 27

By Daily Republic Syndicated Content | From Page: A6

 
Frank and Ernest April 27

By Daily Republic Syndicated Content | From Page: A6

Peanuts April 27

By Daily Republic Syndicated Content | From Page: A6

 
Dilbert April 27

By Daily Republic Syndicated Content | From Page: A6

Baby Blues April 27

By Daily Republic Syndicated Content | From Page: A6

 
Cryptoquote April 27

By Daily Republic Syndicated Content | From Page: A7

Word Sleuth April 27

By Daily Republic Syndicated Content | From Page: A7

 
Sudoku April 27

By Daily Republic Syndicated Content | From Page: A7

Bridge April 27

By Daily Republic Syndicated Content | From Page: A7

 
Crossword April 27

By Daily Republic Syndicated Content | From Page: A7